This website uses cookies to store user session information. By using our website you consent to our terms of use. Read more
I agree
"Mobilitas Pluss Postdoctoral Researcher Grant / Mobilitas Pluss järeldoktoritoetus" project MOBJD512
MOBJD512 "The discovery of novel biomarkers for non-invasive diagnostics of melanoma (1.01.2020−31.12.2021)", Helena Sork, University of Tartu, Faculty of Science and Technology, Institute of Technology.
MOBJD512
Uudsete biomarkerite avastamine melanoomi mitteinvasiivseks diagnostikaks
The discovery of novel biomarkers for non-invasive diagnostics of melanoma
1.01.2020
31.12.2021
R&D project
Mobilitas Pluss Postdoctoral Researcher Grant / Mobilitas Pluss järeldoktoritoetus
ETIS classificationSubfieldCERCS classificationFrascati Manual classificationPercent
1. Biosciences and Environment1.12. Biotechnology, Molecular Biology, Cell Biology, Biophysics and Economic and Technological Research relating to Bio- and Environmental SciencesB200 Cytology, oncology, cancerology1.6 Biological sciences100,0
PeriodSum
01.01.2020−31.12.202180 883,55 EUR
80 883,55 EUR

Melanoom of kõige agressiivsem nahavähi vorm, põhjustades 80% nahavähiga seotud surmajuhtumitest. Nagu kõigi vähkkasvajate puhul, on parimaks elulemust soodustavaks meetmeks kasvaja varajane, eelistatult mitteinvasiivne avastamine. Ökonoomne, kiire ja korduvat analüüsi võimaldav kehavedelikel põhinev testimine on pälvinud poolehoidu ka vähidiagnostikas. Sellegipoolest on ilmselgeks kitsaskohaks usaldusväärsete melanoomi biomarkerite puudus. Käesoleva uuringu eesmärgiks on leida uudseid kehavedelikes leiduvaid makromolekule, kasutamaks neid melanoomi varaseks diagnostikaks. Antud eesmärgi saavutamiseks kasutatakse nii kõrge läbilaskevõimega meetodeid kui ka bioaktiivsete sekreteeritud molekulide spetsiifilist rikastamist. Projekti tulemused annavad nii uusi teadmisi melanoomi bioloogiast kui ka soodustavad vähkkasvajat tuvastava kehavedelikel põhineva diagnostilise testi loomist.
Melanoma is the most aggressive type of skin cancer, accounting for 80% of skin cancer related deaths. As with all cancers, the key to an improved disease outcome is early detection of the tumor which could preferably be obtained via non-invasive methods. The economical, rapid and repeated sampling opportunities of liquid biopsy-based testing have paved their way also to cancer diagnostics. Yet, lack of reliable melanoma biomarkers still remains a major bottleneck. This study aims to identify novel circulating macromolecules that could serve as early diagnostic markers for melanoma identification from liquid-biopsies. The aim will be achieved by employing high-throughput methodologies and by specifically enriching for the bioactive portion of the secretome. The results from the present study will advance the knowledge in melanoma cancer biology and could serve as a basis of developing a liquid biopsy-based diagnostic test to improve melanoma detection.